<DOC>
	<DOCNO>NCT00304863</DOCNO>
	<brief_summary>The purpose study determine whether dietary supplementation Lactobacillus GG reduce rate failure relapse follow treatment CDAD metronidazole .</brief_summary>
	<brief_title>Addition Lactobacillus Metronidazole Treatment CDAD</brief_title>
	<detailed_description>Clostridium difficile associate disease ( CDAD ) , nearly always follow antibiotic therapy , become increasingly common important American hospital , cause substantial morbidity mortality . Metronidazole recommend treatment condition . We recently report ( Clin Infect Dis , June 2005 ) treatment metronidazole associate 22 % rate failure 28 % rate relapse . No medication show effective . There substantial theory limit data suggest dietary supplementation non-pathogenic normal bowel bacteria benefit patient . Lactobacillus GG best-standardized extensively studied agent .</detailed_description>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Enterocolitis</mesh_term>
	<mesh_term>Enterocolitis , Pseudomembranous</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Subjects identify base diagnosis CDAD . This diagnosis make base presence diarrhea , fever , abdominal pain and/or leukocytosis together positive fecal assay Clostridium difficile toxin Patients unable take oral medication underlie gastrointestinal disease colonostomy exclude . Patients currently take penicillin , cephalosporin , quinolones tetracycline exclude drug active Lactobacillus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CDAD</keyword>
	<keyword>Clostridium difficile Associated Diarrhea</keyword>
</DOC>